Not Your Grandfather’s Diabetes Kit: Eli Lilly’s Smart Ring Bet and Modular Medical’s Pivot Pump Rewire the Care Stack -( $LLY $MODD )

Eli Lilly and Company’s (NYSE: LLY) recent equity investment in ŌURA Health and the Oura Ring ecosystem, paired with Modular Medical’s (NASDAQ: MODD) launch of its Pivot tubeless insulin patch pump, is giving Wall Street a preview of what next‑generation metabolic care could look like when molecules, wearables, and daily routines finally start reading from the same script. The emerging narrative for investors: diabetes and obesity management are shifting from isolated prescriptions to continuous, data‑rich ecosystems—built to be clinically rigorous, but also, at long last, livable.

Lilly’s Smart Ring Move: Fingerprints on the Future of Care

Eli Lilly has taken an equity stake in ŌURA Health, maker of the Oura Ring, adding a smart, sensor‑heavy accessory to its growing cardiometabolic toolbox. With Lilly’s capital, ŌURA aims to accelerate the development of connected, personalized health tools that reflect its conviction that the future of care will be more integrated into how people actually live—sleep, move, recover, and stress—not just how they test in the clinic. ŌURA has already leaned into obesity and metabolic health, including GLP‑1 Insights, a feature designed to give users a holistic, data‑grounded view of their progress on GLP‑1 receptor agonist therapies. For Lilly—whose pipeline and portfolio are deeply tied to cardiometabolic drugs—this investment is less about a fashionable ring and more about building a digital engagement layer around its therapies, enabling better adherence, richer real‑world data, and tighter feedback loops between patient behavior and treatment outcomes. ŌURA has confirmed that Eli Lilly made an equity investment as part of its fundraising activities, including a Series E round that pushed the company toward an approximately $11 billion valuation. However, the press materials and follow‑on coverage clearly state that the size of Lilly’s stake was not detailed.

Molecules Meet Micro‑Behaviors

The Lilly–ŌURA partnership underscores a structural shift: cardiometabolic care is moving from episodic snapshots to continuous monitoring, from occasional lab values to real‑time signal analysis. Sleep quality, readiness, activity, and recovery—the core biometric domains of the Oura Ring—become inputs into a more nuanced care loop, allowing therapy decisions to be calibrated not only to weight and A1c, but to how a patient’s daily life and physiology are trending between visits. For investors, this re‑casts Lilly as not just a seller of high‑margin molecules but a participant in a broader platform play where software, hardware, and pharmaceuticals intersect. That opens optionality around digital companions for GLP‑1 and insulin therapy, AI‑powered adherence tools, and outcome‑based care models, all of which can deepen Lilly’s moat in a fiercely competitive obesity and diabetes market.

Modular Medical’s Pivot: Insulin, Made Tubeless and Tolerable

While Lilly builds out the data layer, Modular Medical is tackling a more tangible, everyday problem: making insulin pump therapy simpler to learn and less intimidating to live with via its Pivot tubeless insulin patch pump. Pivot is a removable, two‑part, fully electronic tubeless patch pump with a 3 mL reservoir, purpose‑built for adults on multiple daily injections—the “almost‑pumpers” who have hesitated to adopt traditional pumps due to complexity, cost, or lifestyle friction. Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin‑Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion‑Dollar Market, which squarely positions the product at the center of a sizeable and historically under‑served segment of diabetes technology demand.

Pivot won FDA 510(k) clearance and has begun commercial rollout, with starter kits shipping to endocrinology practices and first patients now using the system for real‑world insulin therapy. The device features intuitive, one‑button operation for bolus delivery, a flexible wearable form factor designed to support daily activities like showering and sports, and no need for battery charging, all while maintaining clinical accuracy and connectivity. By focusing on simplicity, affordability, and everyday usability, Modular Medical is positioning Pivot to expand the pump market into the large, underpenetrated universe of adults who have stayed on injections despite being clear candidates for technology‑enabled insulin delivery.

Ecosystems, Not One‑Off Trades

For investors, Lilly’s ŌURA stake signals strategic confidence in the durability of its cardiometabolic franchise and a willingness to invest around the edges of its drugs to build a more comprehensive, digitally supported care ecosystem. That ecosystem—combining GLP‑1 therapies, telehealth via LillyDirect, and behavior‑sensing wearables—can generate real‑world engagement data, strengthen payer discussions, and support differentiated patient experiences that are increasingly hard for competitors to replicate.

Modular Medical, meanwhile, offers a smaller‑cap, high‑beta expression of the same secular trend: chronic disease management is moving toward devices that are less complex and more humane, targeting an estimated majority of insulin‑dependent adults who remain on multiple daily injections. In a world where obesity and diabetes prevalence remain elevated, and where investors are hungry for scalable, patient‑centric solutions, the combination of Lilly’s data‑driven ecosystem and Modular’s practical, tubeless Pivot pump suggests that the next leg of value creation will reward companies that can make advanced therapy both clinically powerful and genuinely livable.

Takeaways

• Eli Lilly and Company (LLY) has made an equity investment in ŌURA Health and the Oura Ring platform to accelerate connected, personalized tools for cardiometabolic care.
• ŌURA’s GLP‑1 Insights feature aligns with Lilly’s obesity and diabetes strategy by offering users a holistic, data‑driven view of GLP‑1 therapy progress.
• Modular Medical (MODD) has FDA‑cleared and commercially launched Pivot, a tubeless, removable insulin patch pump designed for adult “almost‑pumpers” seeking a simpler transition from multiple daily injections—and explicitly aimed at a large, multibillion‑dollar, underserved insulin‑dependent population.
• Taken together, these moves highlight an investable trend: diabetes and obesity care are evolving into continuous, integrated ecosystems where drugs, devices, and wearables collaborate, creating long‑duration, investor‑magnetic narratives in metabolic health.

The Sources

[1] Lilly Makes an Equity Investment in Oura, Supporting … https://ouraring.com/blog/lilly-equity-investment/
[2] Modular Medical launches Pivot tubeless insulin patch pump https://www.drugdeliverybusiness.com/modular-medical-launches-pivot-tubeless-pump/
[3] Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps https://www.morningstar.com/news/accesswire/1181878msn/modular-medical-announces-shipment-of-pivot-tubeless-patch-pumps
[4] ŌURA and Lilly join forces to harmonise drug-wearable obesity care https://www.pharmaceutical-technology.com/newsletters/lilly-lillydirect-oura-obesity-partnership/
[5] Pivot https://pivotpump.com/
[6] Eli Lilly backs smart-ring maker Ōura in Series E to support … https://app.dealroom.co/news/note/eli-lilly-backs-smart-ring-maker-ura-in-series-e-to-support-glp-1-patients
[7] Eli Lilly makes investment in Oura for GLP-1 users https://www.linkedin.com/news/story/eli-lilly-makes-investment-in-oura-for-glp-1-users-9077226/
[8] Pivot Modular Medical’s Next‑Gen Insulin Patch Pump https://www.precedenceresearch.com/news/modular-medical-pivot-insulin-patch-pump
[9] Modular Medical announces first patients are using Pivot … https://www.hmenews.com/article/modular-medical-announces-first-patients-are-using-pivot-insulin-pump